Customer Service 1 (888) 261-2693
Please enter Search keyword. Advanced Search
Home About Us Resources Archive Free Reports Market Window

Biotech Is a Screaming 'Melt Up' Buy Today

By Dr. Steve Sjuggerud
Monday, November 6, 2017

The biotech sector recently fell by 8% in three weeks.
 
I believe the bust is overdone. And now is a great moment to swoop in and buy...
 
Biotech was by far the best-performing sector in the last great "Melt Up," when stocks soared at the end of the 1990s bull market. And I expect it will perform well again as today's Melt Up starts to pick up steam...
 
The main thing most people remember from the great dot-com boom is that tech stocks soared.
 
But take a look at this chart... It shows that biotech stocks (as measured by the Nasdaq Biotechnology Index) dramatically outperformed tech stocks in the final months of the last great Melt Up.
 

The iShares Nasdaq Biotechnology Fund (IBB) has had a rough few weeks. It's down 8% from its most recent peak. Importantly, that has pushed biotech stocks to an "oversold extreme."
 
We measure "overbought" or "oversold" levels with the relative strength index ("RSI") – the typical indicator that tells us when an investment has moved too quickly to the upside or downside.
 
Last week, the RSI in biotech stocks fell to its second-lowest level in the last 10 years.
 
That begs the question – what happened after the MOST extreme level in the last 10 years?
 
Biotech stocks hit their biggest oversold extreme on August 8, 2011. After that, they shot up by more than 40% in just six months. You can see it for yourself in this chart...
 

Of course, longtime readers know I don't like to buy into a downtrend. I want to wait for the uptrend to confirm my idea before I get in.
 
Similarly, with the RSI, I don't want to buy when a stock (or fund) is oversold. That tells me it's hated... But the problem is, it can always get a lot more hated!
 
So I prefer to wait for an uptrend in the RSI, too... to wait for the oversold extreme to go away.
 
Fortunately, that's what we're seeing today. The oversold extreme appears to be gone in biotech. It looks like the downtrend might be over, and we could be right at the start of an uptrend. This chart shows the details...
 

This week, our True Wealth Systems computers went against what I'm telling you today. They said to sell biotech – and they're usually right.
 
But there are times when I disagree with our computers. This is one of those times. I'm willing to go against them today because I believe this is the right setup – one that's giving us a huge opportunity.
 
You know I'm a strong believer in what I call the Melt Up. And you know that biotech was a dramatic outperformer in the last great Melt Up. I expect biotech will be a great performer in this Melt Up, as well. So this mini-bust in biotech stocks gives us a great entry point...
 
This might be your last – and best! – chance to get into biotech stocks before they take off in the Melt Up.
 
Take advantage of it...
 
Good investing,
 
Steve




Further Reading:

Steve says biotech stocks are a great way to profit as the bull market enters its final innings. Check out his most recent Melt Up essays here:
 

Market Notes


NEW HIGHS OF NOTE LAST WEEK
 
Wal-Mart (WMT)... discount retailer
Dollar Tree (DLTR)... dollar stores
C.H. Robinson Worldwide (CHRW)... shipping technology
Apple (AAPL)... iPhones, iPads, and more
Intel (INTC)... semiconductors
Adobe Systems (ADBE)... computer software
Match (MTCH)... online dating
Interactive Brokers (IBKR)... online brokerage
Activision Blizzard (ATVI)... video games
Churchill Downs (CHDN)... horse racing and gambling
Madison Square Garden (MSG)... sports and concerts
Vail Resorts (MTN)... ski resorts
Hyatt Hotels (H)... hotels
Marriott (MAR)... hotels
Fiat Chrysler Automobiles (FCAU)... cars and trucks
Honda Motor (HMC)... cars and trucks
Toyota Motor (TM)... cars and trucks
Royal Dutch Shell (RDS-A)... oil giant
Rayonier (RYN)... timberland
Deere (DE)... tractors and farming equipment
Owens Corning (OC)... roofing and insulation
Consolidated Edison (ED)... utilities
Exelon (EXC)... utilities
Cigna (CI)... health insurance
Becton Dickinson (BDX)... needles and syringes

NEW LOWS OF NOTE LAST WEEK
 
GGP (GGP)... mall REIT
JC Penney (JCP)... retail "old guard"
Nordstrom (JWN)... retail "old guard"
Under Armour (UAA)... sports apparel
CBS (CBS)... television
Viacom (VIAB)... television

premium teaser

This sector could soar triple digits as the Melt Up continues...
 
Biotech stocks aren't the only sector to soar during a Melt Up. Today, it's time to buy in with this fund...
 

Recent Articles
Legal Notices: Stansberry Research LLC (Stansberry Research) is a publishing company and the indicators, strategies, reports, articles and all other features of our products are provided for informational and educational purposes only and should not be construed as personalized investment advice. Our recommendations and analysis are based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.

 

Readers should be aware that trading stocks and all other financial instruments involves risk. Past performance is no guarantee of future results, and we make no representation that any customer will or is likely to achieve similar results.

 

Our testimonials are the words of real subscribers received in real letters, emails, and other feedback who have not been paid for their testimonials. Testimonials are printed under aliases to protect privacy, and edited for length. Their claims have not been independently verified or audited for accuracy. We do not know how much money was risked, what portion of their total portfolio was allocated, or how long they owned the security. We do not claim that the results experienced by such subscribers are typical and you will likely have different results.

 

Any performance results of our recommendations prepared by Stansberry Research are not based on actual trading of securities but are instead based on a hypothetical trading account. Hypothetical performance results have many inherent limitations. Your actual results may vary.

 

Stansberry Research expressly forbids its writers from having a financial interest in any security they recommend to our subscribers. And all Stansberry Research (and affiliated companies), employees, and agents must wait 24 hours after an initial trade recommendation is published on the Internet, or 72 hours after a direct mail publication is sent, before acting on that recommendation.

 

© 2024 Stansberry Research, LLC. | Privacy Policy| Customer Service
Stansberry Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This website may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry Research, LLC. 1125 N Charles St. Suite 500, Baltimore MD 21202.